In May 2001, the world's first targeted drug, Gleevec, was approved for marketing, marking the treatment of chronic myelogenous leukemia (hereafter referred to as CML) using tyrosine kinase inhibitors (hereafter referred to as TKIs). referred to in) is entering the era of. The scientific name of Gleevec is imatinib mesylate, which is a first-generation TKI.
Gleevec's patent for treating leukemia expired in April 2013. Three domestic generic drugs have received production approval and will soon be ready for mass production. 
These drugs have anti-tumor cell proliferation and cytotoxic effects. After use, they can temporarily control the increase in white blood cells and shrink the spleen, but they cannot delay the progression of the disease.

For more info- https://www.medixocentre.com/gleevec-imatinib-cost